



MEDIA RELEASE

ASCEND EXPANDS ITS SCIENTIFIC ADVISORY BOARD

Melbourne Australia, August 11, 2016 – Ascend Biopharmaceuticals Ltd, a Melbourne based, clinical stage immune-oncology company developing novel cancer treatments, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of Professor Edward Mocarski. The appointment is a continuation of the company’s efforts to build a world-class advisory board in the area of regulated cell death and immuno-regulation.

Professor Mocarski is currently the Robert W. Woodruff Professor of Microbiology and Immunology at Emory University and he previously served as Chairman of the Department of Microbiology and Immunology and Associate Dean for Research at Stanford University. Dr. Mocarski is recognized as having made significant contributions in the biology, pathogenesis and latency of herpesviruses and more recently in the understanding of how viruses can subvert cell death programs. Studies from his laboratory have identified novel programmed cell death pathways that are increasingly being shown to have critical roles in a wide range of diseases. His work has shown that these ancient pathways can link the innate host defense with the adaptive arms of the immune system.

Dr Clement Leong, Chief Executive Officer of Ascend, commented "We are excited to have someone of the caliber of Professor Mocarski join us at this juncture, where his expertise will have an important impact on our advancing clinical and preclinical pipelines. Professor Mocarski is at the vanguard of an extremely exciting area of biology that has begun to provide insights on how we can target regulated cell death pathways to create broadly applicable and durable cancer therapies."

-END-

For more information, please contact:



Clement Leong
Ascend Biopharmaceuticals, CEO
T: + 61 3 8606 3401
E: clementleong@ascendbiopharma.com

About Ascend Biopharmaceuticals

Ascend is a clinical-stage company developing innovative cancer treatments. The company focuses on identifying disease settings where targeting the disease microenvironment or key cell types can bring about meaningful improvements in clinical outcomes.

Ascend has two clinical stage immunotherapy programs that have undergone previous clinical evaluation. The first product, ASN-002, will be assessed in basal cell carcinoma patients while the second product, ASN-004, is a pan-cancer therapeutic vaccine that will be studied in early stage breast cancer. For more information, please visit www.ascendbiopharma.com or call +61 3 8606 3488.